{"protocolSection":{"identificationModule":{"nctId":"NCT01579916","orgStudyIdInfo":{"id":"CD-VA-FluMist-1114"},"organization":{"fullName":"MedImmune LLC","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults","officialTitle":"A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults"},"statusModule":{"statusVerifiedDate":"2013-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-05"},"primaryCompletionDateStruct":{"date":"2012-11","type":"ACTUAL"},"completionDateStruct":{"date":"2012-11","type":"ACTUAL"},"studyFirstSubmitDate":"2012-04-16","studyFirstSubmitQcDate":"2012-04-17","studyFirstPostDateStruct":{"date":"2012-04-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-12-16","resultsFirstSubmitQcDate":"2013-12-16","resultsFirstPostDateStruct":{"date":"2014-02-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-12-16","lastUpdatePostDateStruct":{"date":"2014-02-03","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MedImmune LLC","class":"INDUSTRY"},"collaborators":[{"name":"AstraZeneca","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent intranasal FluMist vaccine.\n\nThree hundred healthy adults will receive a single dose of vaccine or placebo and will be followed for 180 days after study vaccination.","detailedDescription":"This prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age. Eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray. Randomization will be stratified by site.\n\nThis study will be conducted at 3 sites in the United States of America. Each subject will receive one dose of investigational product on Study Day 1. The duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination."},"conditionsModule":{"conditions":["Influenza"],"keywords":["Trivalent, Influenza, FluMist, Vaccine, Prevention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":303,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Trivalent Influenza Virus Vaccine","type":"EXPERIMENTAL","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.","interventionNames":["Biological: Trivalent Influenza Virus Vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.","armGroupLabels":["Trivalent Influenza Virus Vaccine"]},{"type":"OTHER","name":"Placebo","description":"Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Reporting Fever Within 7 Days Post Vaccination","description":"A comparison of the rate of fever, defined as oral temperature greater than or equal to 101 degrees Fahrenheit, reported during the 7 days post administration of investigational product between the trivalent influenza virus vaccine and placebo groups.","timeFrame":"Study Days 1 - 8"}],"secondaryOutcomes":[{"measure":"Percentage of Participants Reporting Other Solicited Symptoms Within 7 Days Post Vaccination","description":"Solicited symptoms were events that were considered likely to occur post dosing. Solicited symptoms for this study are listed below.","timeFrame":"Study Days 1- 8"},{"measure":"Percentage of Participants Reporting Any Adverse Event (AE) Within 7 Days Post Vaccination","description":"Percentage of participants reporting at least one AE between Days 1 and 8. Investigational product was administered on Day 1.","timeFrame":"Study Days 1 - 8"},{"measure":"Percentage of Participants Reporting Other Solicited Symptoms Within 14 Days Post Vaccination","description":"Solicited symptoms were events that were considered likely to occur post dosing. Solicited symptoms for this study are listed below.","timeFrame":"Study Days 1 - 15"},{"measure":"Percentage of Participants Reporting Any Adverse Event (AE) Within 14 Days Post Vaccination","description":"Percentage of participants reporting at least one AE between Days 1 and 15. Investigational product was administered on Day 1.","timeFrame":"Study Days 1 - 15"},{"measure":"Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 28 Days Post Vaccination","description":"Percentage of participants reporting at least one SAE between Days 1 and 29. Investigational product was administered on Day 1.","timeFrame":"Study Days 1 - 29"},{"measure":"Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 180 Days Post Vaccination","description":"Percentage of participants reporting at least one SAE between Days 1 and 181. Investigational product was administered on Day 1.","timeFrame":"Study Days 1 - 181"},{"measure":"Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 28 Days Post Vaccination","description":"An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature and assessed by the investigator as medically significant. Such events were assessed between Day 1 and Day 29. Investigational product was administered on Day 1.","timeFrame":"Study Days 1 - 29"},{"measure":"Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 180 Days Post Vaccination","description":"An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature and assessed by the investigator as medically significant. Such events were assessed between Day 1 and Day 181. Investigational product was administered on Day 1.","timeFrame":"Study Days 1 - 181"},{"measure":"Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 7 Days Post Vaccination","description":"Percentage of participants who used an antipyretic or analgesic agent between Days 1 and 8. Investigational product administration occurred on Day 1.","timeFrame":"Study Days 1 - 8"},{"measure":"Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 14 Days Post Vaccination","description":"Percentage of participants who used an antipyretic or analgesic agent between Days 1 and 15. Investigational product administration occurred on Day 1.","timeFrame":"Study Days 1 - 15"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18 through 49 years at the time of investigational product administration\n2. Written informed consent and any locally required authorization (ie, HIPAA in the USA) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations\n3. Females of childbearing potential who are sexually active with a nonsterilized male partner must use effective contraception for 30 days prior to study vaccination, and must agree to continue using such precautions for 60 days after study vaccination\n4. Nonsterilized males who are sexually active with a female partner of child-bearing potential must use an effective method of contraception from prior to study vaccination amd must agree to continue using such precautions for at least 30 days after receipt study vaccination\n5. Healthy by medical history and physical examination\n6. Female subjects of child-bearing potential must also have a negative urine or blood pregnancy test at screening and, if screening and Day 1 do not occur on the same day, on the day of vaccination prior to randomization.\n7. Subject available by telephone\n8. Ability to understand and comply with the requirements of the protocol, as judged by the investigator\n9. Ability to complete follow-up period of 180 days after dosing as required by the protocol\n\nExclusion Criteria:\n\n1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results\n2. Concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (Day 181)\n3. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals\n4. History of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations\n5. History of hypersensitivity to gentamicin\n6. Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (eg, asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year\n7. Acute febrile (\\> 100.0°F oral or equivalent) and/or clinically significant respiratory illness (eg, cough or sore throat) within 14 days prior to randomization\n8. Any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy\n9. History of Guillain-Barré syndrome\n10. A household contact who is severely immunocompromised (eg, hematopoietic stem cell transplant recipient, during those periods in which the immunocompromised individual requires care in a protective environment); additionally, subject should avoid close contact with severely immunocompromised individuals for at least 21 days after study vaccination\n11. Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 30 days after study vaccination (use of licensed agents for indications not listed in the package insert is permitted)\n12. Receipt of any non-study vaccine within 30 days prior to randomization, or expected receipt through 30 days after study vaccination\n13. Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 14 days after study vaccination\n14. Administration of intranasal medications within 14 days prior to randomization, or expected receipt through 14 days after study vaccination\n15. Receipt of influenza antiviral therapy or antiviral agents within 48 hours prior to study vaccination or expected receipt of influenza antiviral therapy or antiviral agents through 14 days after study vaccination\n16. Known or suspected mitochondrial encephalomyopathy\n17. Nursing mother","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Raburn Mallory, MD","affiliation":"MedImmune LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Research Site","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eligible participants were randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray. Randomization was stratified by site.","recruitmentDetails":"303 participants participated in the study from 21May2012 (date of first written informed consent) through 30Nov2012 (date of last participant visit).","groups":[{"id":"FG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"FG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"242"},{"groupId":"FG001","numSubjects":"61"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"234"},{"groupId":"FG001","numSubjects":"59"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"BG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."},{"id":"BG002","title":"TOTAL","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"242"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"303"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32.7","spread":"9.1"},{"groupId":"BG001","value":"32.0","spread":"8.8"},{"groupId":"BG002","value":"32.6","spread":"9.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"136"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"165"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"138"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Reporting Fever Within 7 Days Post Vaccination","description":"A comparison of the rate of fever, defined as oral temperature greater than or equal to 101 degrees Fahrenheit, reported during the 7 days post administration of investigational product between the trivalent influenza virus vaccine and placebo groups.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Study Days 1 - 8","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison of the rate of fever between the 2 treatment groups was based on the upper limit of the two-sided 95% exact confidence intervals (CIs) for the rate increase (trivalent influenza virus vaccine minus placebo) evaluated against the prespecified equivalence criterion of 5 percentage points","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"H0 (null): Rate difference greater than or equal to 5 percentage points. This corresponds to a null hypothesis of: HA (alternative): rate difference \\< 5 percentage points.","statisticalMethod":"Score statistic","paramType":"Rate difference","paramValue":"-1.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.9","ciUpperLimit":"0.6"}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Other Solicited Symptoms Within 7 Days Post Vaccination","description":"Solicited symptoms were events that were considered likely to occur post dosing. Solicited symptoms for this study are listed below.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Study Days 1- 8","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Any symptom","categories":[{"measurements":[{"groupId":"OG000","value":"38.6"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Fever > 100 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Fever >/= 101 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Fever > 102 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever > 103 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Runny nose","categories":[{"measurements":[{"groupId":"OG000","value":"18.3"},{"groupId":"OG001","value":"8.3"}]}]},{"title":"Sore throat","categories":[{"measurements":[{"groupId":"OG000","value":"14.1"},{"groupId":"OG001","value":"5.0"}]}]},{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"4.1"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Muscle aches","categories":[{"measurements":[{"groupId":"OG000","value":"5.0"},{"groupId":"OG001","value":"3.3"}]}]},{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"3.3"}]}]},{"title":"Decreased activity (tiredness)","categories":[{"measurements":[{"groupId":"OG000","value":"8.7"},{"groupId":"OG001","value":"6.7"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"15.8"},{"groupId":"OG001","value":"10.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Any Adverse Event (AE) Within 7 Days Post Vaccination","description":"Percentage of participants reporting at least one AE between Days 1 and 8. Investigational product was administered on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Study Days 1 - 8","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5"},{"groupId":"OG001","value":"6.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Other Solicited Symptoms Within 14 Days Post Vaccination","description":"Solicited symptoms were events that were considered likely to occur post dosing. Solicited symptoms for this study are listed below.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Study Days 1 - 15","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Perecentage of participants reporting any symptom","categories":[{"measurements":[{"groupId":"OG000","value":"41.5"},{"groupId":"OG001","value":"25.0"}]}]},{"title":"Fever > 100 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Fever >/= 101 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Fever > 102 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever > 103 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Runny nose","categories":[{"measurements":[{"groupId":"OG000","value":"19.1"},{"groupId":"OG001","value":"13.3"}]}]},{"title":"Sore throat","categories":[{"measurements":[{"groupId":"OG000","value":"14.9"},{"groupId":"OG001","value":"5.0"}]}]},{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG001","value":"3.3"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Muscle aches","categories":[{"measurements":[{"groupId":"OG000","value":"5.8"},{"groupId":"OG001","value":"3.3"}]}]},{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"3.3"}]}]},{"title":"Decreased activity (tiredness)","categories":[{"measurements":[{"groupId":"OG000","value":"8.7"},{"groupId":"OG001","value":"8.3"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"17.4"},{"groupId":"OG001","value":"11.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Any Adverse Event (AE) Within 14 Days Post Vaccination","description":"Percentage of participants reporting at least one AE between Days 1 and 15. Investigational product was administered on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Study Days 1 - 15","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9"},{"groupId":"OG001","value":"6.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 28 Days Post Vaccination","description":"Percentage of participants reporting at least one SAE between Days 1 and 29. Investigational product was administered on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Study Days 1 - 29","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 180 Days Post Vaccination","description":"Percentage of participants reporting at least one SAE between Days 1 and 181. Investigational product was administered on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Study Days 1 - 181","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"1.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 28 Days Post Vaccination","description":"An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature and assessed by the investigator as medically significant. Such events were assessed between Day 1 and Day 29. Investigational product was administered on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Study Days 1 - 29","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 180 Days Post Vaccination","description":"An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature and assessed by the investigator as medically significant. Such events were assessed between Day 1 and Day 181. Investigational product was administered on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Study Days 1 - 181","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 7 Days Post Vaccination","description":"Percentage of participants who used an antipyretic or analgesic agent between Days 1 and 8. Investigational product administration occurred on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Study Days 1 - 8","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"3.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 14 Days Post Vaccination","description":"Percentage of participants who used an antipyretic or analgesic agent between Days 1 and 15. Investigational product administration occurred on Day 1.","populationDescription":"All participants who received a single dose of investigational product (trivalent influenza virus vaccine = 241; placebo = 60).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Study Days 1 - 15","groups":[{"id":"OG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1."},{"id":"OG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"3.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse events were collected from the time of investigational product administration through Day 15. Serious adverse events were collected from the time of study drug administration through Day 181.","eventGroups":[{"id":"EG000","title":"Trivalent Influenza Virus Vaccine","description":"Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.","seriousNumAffected":1,"seriousNumAtRisk":241,"otherNumAffected":19,"otherNumAtRisk":241},{"id":"EG001","title":"Placebo","description":"Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.","seriousNumAffected":1,"seriousNumAtRisk":60,"otherNumAffected":4,"otherNumAtRisk":60}],"seriousEvents":[{"term":"Extradural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Multiple fractures","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]}],"otherEvents":[{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Post-traumatic headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Increased upper airway secretion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication."},"pointOfContact":{"title":"Raburn Mallory, MD/Senior Director Clinical Development","organization":"MedImmune, LLC","email":"malloryr@medimmune.com","phone":"301-398-0000"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}